Literature DB >> 10089071

Epilepsy and gliomas: incidence and treatment in 119 patients.

A Pace1, L Bove, P Innocenti, A Pietrangeli, C M Carapella, P Oppido, L Raus, E Occhipinti, B Jandolo.   

Abstract

One hundred and nineteen consecutive patients affected by supratentorial gliomas were studied in order to determine the incidence of seizure at diagnosis, the occurrence of subsequent seizures and the efficacy of anticonvulsant treatment. The overall incidence of seizures as presentation symptom was 52% (62 patients). Preoperative seizures were present in 83% of patients affected by low-grade astrocytoma, in 46% of patients affected by anaplastic astrocytoma and in 36% of patients affected by glioblastoma. Postoperative epilepsy refractory to anticonvulsant treatment significantly related to low-grade histology and presence of preoperative seizures occurred in 48% of patients. Adverse effects associated with anticonvulsants were observed in 33.8% of patients treated with phenobarbital, 14.3% in the group treated with carbamazepine and 12% of patients treated with vigabatrin. We conclude that anticonvulsant treatment in patients affected by gliomas is often ineffective and prophylactic treatment should be discontinued after 6 months in patients preoperative seizures free. In patients with high risk of seizures antiepileptic drugs with good efficacy and lower incidence of adverse effects than phenobarbital are indicated.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10089071

Source DB:  PubMed          Journal:  J Exp Clin Cancer Res        ISSN: 0392-9078


  23 in total

Review 1.  Brain Tumor-Related Epilepsy: a Current Review of the Etiologic Basis and Diagnostic and Treatment Approaches.

Authors:  Jeffrey M Politsky
Journal:  Curr Neurol Neurosci Rep       Date:  2017-09       Impact factor: 5.081

2.  Comorbid conditions associated with glioblastoma.

Authors:  James L Fisher; Sadie Palmisano; Judith A Schwartzbaum; Tobias Svensson; Stefan Lönn
Journal:  J Neurooncol       Date:  2014-01-11       Impact factor: 4.130

3.  Seizure characteristics and outcomes in 508 Chinese adult patients undergoing primary resection of low-grade gliomas: a clinicopathological study.

Authors:  Gan You; Zhi-Yi Sha; Wei Yan; Wei Zhang; Yong-Zhi Wang; Shao-Wu Li; Lin Sang; Zi Wang; Gui-Lin Li; Shou-Wei Li; Yi-Jun Song; Chun-Sheng Kang; Tao Jiang
Journal:  Neuro Oncol       Date:  2011-12-19       Impact factor: 12.300

4.  Anaplastic astrocytoma.

Authors:  Sean A Grimm; Thomas J Pfiffner
Journal:  Curr Treat Options Neurol       Date:  2013-06       Impact factor: 3.598

Review 5.  Anaplastic astrocytoma.

Authors:  Sean A Grimm; Marc C Chamberlain
Journal:  CNS Oncol       Date:  2016-05-27

Review 6.  Clinical Management of Seizures in Patients With Low-Grade Glioma.

Authors:  Anna F Piotrowski; Jaishri Blakeley
Journal:  Semin Radiat Oncol       Date:  2015-02-23       Impact factor: 5.934

7.  Oxcarbazepine monotherapy in patients with brain tumor-related epilepsy: open-label pilot study for assessing the efficacy, tolerability and impact on quality of life.

Authors:  M Maschio; L Dinapoli; F Sperati; A Fabi; A Pace; A Vidiri; P Muti
Journal:  J Neurooncol       Date:  2011-08-17       Impact factor: 4.130

8.  Prospective assessment of health-related quality of life in patients with low-grade glioma: a single-center experience.

Authors:  Cagdas Yavas; Faruk Zorlu; Gokhan Ozyigit; Murat Gurkaynak; Guler Yavas; Deniz Yuce; Mustafa Cengiz; Ferah Yildiz; Fadil Akyol
Journal:  Support Care Cancer       Date:  2011-10-08       Impact factor: 3.603

9.  Seizures during the management of high-grade gliomas: clinical relevance to disease progression.

Authors:  Young-Hoon Kim; Chul-Kee Park; Tae Min Kim; Seung Hong Choi; Yu Jung Kim; Byung Se Choi; Jung Ho Han; Se-Hoon Lee; Chae-Yong Kim; In Ah Kim; Dae Seog Heo; Il Han Kim; Dong Gyu Kim; Hee-Won Jung
Journal:  J Neurooncol       Date:  2013-03-04       Impact factor: 4.130

Review 10.  Seizures and epilepsy in cancer: etiologies, evaluation, and management.

Authors:  Jai Grewal; Harpreet K Grewal; Arthur D Forman
Journal:  Curr Oncol Rep       Date:  2008-01       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.